Clinical trials: CTLA4
Healthy Male Volunteers
A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects
Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX13 with YERVOY® Injection in Healthy Chinese Male Subjects
- Trial name
- NCT06159101
- Testing
- HLX13, CN-sourced ipilimumab, EU-sourced ipilimumab group
- Where
- China
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
Healthy Male Adults Participants
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations
This study is to evaluate the pharmacokinetic (PK) similarity of AK104 (an anti-PD-1/CTLA-4 bispecific antibody) from the proposed new manufacturing site and the approved original site in healthy male participants.
- Trial name
- NCT07619001
- Testing
- AK104 (New Site), AK104 (Original Site)
- Where
- China
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Akeso
Health Volunteer
Clinical Study of Recombinant Humanized CTLA-4-FC Fusion Protein Injection in Healthy Subjects
This is a single-center, randomized, double-blind, does-escalation Phase I Clinical Study that aim to evaluate the tolerability, safety and PK Characteristics of recombinant humanized CTLA-4-FC fusion protein injection in Healthy…
- Trial name
- NCT05256719
- Testing
- Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg, Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg, Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Beijing VDJBio Co., LTD.
Cancer, Immune System Disorder
Montreal Immune-Related Adverse Events (MIRAE) Study
Immune checkpoint inhibitors (ICI) are among the most promising approaches to fighting cancer. However, a substantial percentage of patients experience off-target adverse effects in the form of mild to severe inflammation in…
- Conditions
- Cancer, Immune System Disorder, Inflammatory Reaction, Autoimmune Diseases
- Trial name
- MIRAE (NCT05139706)
- Where
- Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
ITP - Immune Thrombocytopenia
"Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children"
the investigators aim in this study to investigate the potential association of single gene polymorphisms of CTLA-4 (SNPs; rs: 3087243) using real-time PCR in children with primary ITP.
- Trial name
- ITP (NCT07014904)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sohag University
Rheumatoid Arthritis
Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
The condition that will be studied is Rheumatoid Arthritis (RA), and in particular, RA patients with moderate to highly active disease who were prescribed Abatacept (Orencia®) (ABA) by their physician during their setting of care…
- Trial name
- NCT05782335
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Hospital for Special Surgery, New York
LRBA Deficiency, CTLA4 Haploinsufficiency
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies
Primary immune deficiencies (PID) are a group of chronic diseases characterized by recurrent infections. Apart from recurrent infections, in some of PIDs autoimmunity, allergy or malignancy could be accompanied to the diseases.
- Trial name
- NCT04377867
- Testing
- Abatacept Injection [Orencia]
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Marmara University
Healthy Male Subjects
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects
The purpose of this study is to evaluate the pharmacokinetic similarity of AK104 with different manufacturing process in healthy male subjects.
- Trial name
- NCT05559554
- Testing
- AK104 (before the change), AK104 (after the change)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Akeso